Home › Spinal Cord Injuries › NCT05302999

Feasibility of Early Gabapentin as an Intervention for Neurorecovery

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Traumatic SCI;
2. All levels of SCI;
3. All severities of SCI, AIS A-D;
4. Age 18 years and older.
5. Agree to participate and start study drug within 120 hours' post-injury.
6. Adequate cognition and communication to provide informed consent

Exclusion Criteria:

1. Presence of moderate/severe traumatic brain injury (TBI) as defined by Glasgow Coma Score (GCS) \< 13 at 120 hours' post-injury.
2. Documented use of gabapentinoids at the time of injury.

About the study

The objective of the proposed study is to conduct the first ever prospective, dose-exploration trial to test the feasibility of early administration of gabapentin as an intervention for neurorecovery. This research project falls under the Intervention Development stage of research as the primary goal is to assess the feasibility of conducting a well-designed intervention efficacy study in the future.

What is being tested

• Gabapentin (drug)
• Placebo (drug)

Sponsor: MetroHealth Medical Center · Participants: 42 · Started: Mar 14, 2022

Contact the study team

• Mayson Moore · Phone: 216-957-3518

Official record on ClinicalTrials.gov — NCT05302999

Locations in the U.S.

Conditions

• Spinal Cord Injuries

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.